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Abstract
Introduction: Ethoxidol is a promising cardioprotective drug, the pharmacological activity of which is based 
on antihypoxic and antioxidant action. Aim and Objective: This study aims to study the cardioprotective 
activity of ethoxydol in monotherapy and combination of ethoxidol and rosuvastatin using Langendorf-
isolated rat heart model. Materials and Methods: Langendorf-isolated hearts were divided into four groups: 
(I) Control, (II) ethoxidol in a small dose (1 × 10−4 g/l), (III) ethoxydol in a large dose (3.8 × 10−4 g/l), and 
(IV) combined use of a large dose of ethoxidol (3.8 × 10−4 g/l) and rosuvastatin (4 × 10−5 g/l). Ischemic 
lesions were modeled with a 60-min pause in heart perfusion. For the study of cardioprotective activity, the 
contractile function of the heart and NADPH activity of myocardiocytes was evaluated by staining sections 
with triphenyltetrazolium chloride. Results: The dose-dependent pharmacological efficacy of ethoxydol was 
established. In addition, the combination of ethoxydol at a concentration of 3.8 × 10−4 g/l with rosuvastatin (4 
× 10−5 g/l) had the greatest effect on the reduction of contractility during the reperfusion period. Conclusion: 
The study of cardioprotective activity showed that in vitro ethoxydol at a dose of 3.8 × 10−4 g/l can significantly 
improve the morphofunctional state of cardiomyocytes, which is manifested in an increase in the proportion 
of postischemic cardiac resumption, reduction of ischemic contracture, and recovery of contractility during 
the reperfusion period.
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INTRODUCTION
Hypoxia is one of the universal pathological processes in many diseases and critical conditions.[1] Therefore, 
issues related to hypoxia go far beyond the 
pathophysiology, become a social problem, 
and require the development of new effective 
methods and pharmacological tools that 
facilitate the body’s adaptation to hypoxia, 
or prevent its development, accelerating the 
normalization of function in the posthypoxic 
period.[2-9] One of the promising drugs with 
antihypoxic and antioxidant orientation of action 
is ethoxydol. The possibility of implementing 
the cardioprotective effect of ethoxidol in 
ischemic myocardial injuries, as well as the 
pharmacological interaction with a group 
of HMG-CoA reductase inhibitors, requires experimental 
verification.
MATERIALS AND METHODS
The experiments were carried out in accordance with the 
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5725–2002, and the rules of laboratory practice approved 
by Order No 708n of the Ministry of Health and Social 
Development of the Russian Federation on August 23, 
2010, in compliance with The European Convention for the 
Protection of Vertebrates Used for Experiments or Other 
Scientific Purposes (Directive 2010/63/EU). The experiments 
were conducted in accordance with The Guidelines for Pre-
clinical Study of Medicinal Products (2012).
The initial number of animals in the groups varied and 
depended on the restoration of contractility in the reperfusion 
period. The total number of hearts that restored work in each 
group was 10. The animals were represented by the following 
groups: (I) Control - reperfusion with a standard Krebs-
Henseleit solution, (II) ethoxidol in a small dose - reperfusion 
with Krebs-Henseleit solution containing 1 × 10−4 g/l of 
ethoxidol, (III) ethoxydol in a large dose - reperfusion with a 
solution Krebs-Henseleit containing 3.8 × 10−4 g/l ethoxydol, 
and (IV) combined use of a large dose of ethoxydol and 
rosuvastatin - reperfusion with Krebs-Henseleit solution 
containing 3.8 × 10−4 g/L ethoxydol and 4 × 10−5 g/l 
rosuvastatin. Hearts were removed from animals under 
combined anesthesia (Xyla premedication 0.5 ml/kg, basic 
anesthesia - Zoletil [50 mg/kg]), the aorta was cannulated 
and immediately connected to a perfusion unit. The perfusion 
unit was a standard 4-heart unit for perfusion of Langendorf-
isolated heart produced by Cardioprotect LLC, St. Petersburg.
In the perfusion column was a standard Krebs-Henseleit 
solution of the following composition (mmol): NaCl - 118.5, 
KCl - 4.7, MgSO
4
/7H2O - 1.2, KH2PO4 - 1.2, CaCl2 - 1.5, 
glucose - 11.1, and NaHCO3 - 25.0. Oxygenation was carried 
out with a mixture of carbon dioxide and oxygen, the pH and 
the temperature of the solution were monitored with a pH 
meter and were 7.4 ± 0.2 at 37°C.
The contractile function of the heart was recorded using a 
polyethylene canister inserted into the left ventricle cavity 
and connected by a tube to a pressure sensor embedded 
in the PhysExpBlackBox software and hardware system 
(manufactured by Cardioprotect LLC, St. Petersburg). 
With the help of the “PhysExp” program, all rats were 
registered with indicators of contractility: Intraventricular 
pressure (IVP, mmHg), heart rate (HR, beats/min), 
maximum speed of contraction (+dp/dt, mm hg/s), and the 
maximum rate of myocardial relaxation (-dp/dt, mm hg/s).
To wash the heart, the heart was perfused with a standard 
Krebs-Henseleit solution for 20 min, after which a total 60-min 
ischemia was simulated by discontinuing the perfusion. 
Reperfusion was carried out for 120 min, after which staining 
was carried out according to a standard procedure with 1% 
triphenyltetrazolium chloride.[10] The area of necrosis of sections 
was analyzed in the program Adobe Photoshop CS. Statistical 
processing of the results included the calculation of arithmetic 
averages (M), standard error of the mean. The significance of 
change was determined using the Mann–Whitney U-test.
RESULTS
Investigation of myocardial functional activity after 
ischemia simulation
After 20 min of perfusion with a standard Krebs-Henseleit 
solution that does not contain the test substances, the 
parameters of the hearts (HR, IVP, contraction rate, and 
relaxation rate) in the control and experimental groups had 
no significant differences. This indicates the same initial 
conditions of the hearts before ischemia and subsequent 
perfusion of the studied substances.
After a 60-min total ischemia, heart reperfusion was activated. 
During reperfusion, the resumption of work occurred within 
20–40 min or did not occur at all. The ratio (%) of the resumed 
hearts is shown in Table 1.
The recovery of the hearts’ work increases with reperfusion with 
Krebs-Henseleit solution containing ethoxydol at a concentration 
of 1 × 10−4 - in comparison with the control group data by 15%, 
at a concentration of 3.8 × 10−4 g/l - by 38%; a combination of 
ethoxydol in a large dose with rosuvastatin - 50%.
When compared with the values of the control group during 
reperfusion with Krebs-Henseleit solution containing 
ethoxydol (3.8 × 10−4 g/l), IVP parameter is significantly higher 
by 30 min - by 80%, by 60 min - by 112%, by 90 min - by 
70%, and by 120 min - by 60% [Table 2]; the speed parameter 
+ dp/dt is higher by 30 min - by 164%, by 60 min - by 110%, 
and by 90 min - by 30%; the speed parameter -dp/dt is 
higher by 30 min - by 164%, by 60 min - by 110%, and by 
120 min - by 38% [Table 2].
When compared with the values of the control group during 
reperfusion with Krebs-Henseleit solution containing a 
combination of ethoxydol (3.8 × 10−4 g/L) with rosuvastatin 4 × 
10−5 g/L, IVP parameter is significantly higher by 30 min - by 
54%, on 60 min - by 154%, on 90 min - by 59%, and on 
120 min - by 88%; the speed parameter + dp/dt is higher 
by 30 min - by 132%, by 60 min - by 122%, by 90 min - by 
44%, and by 120 min - by 38%; the speed parameter -dp/dt 
Table 1: The effect of the reperfusion of ethoxydol 
and the combination of ethoxydol with rosuvastatin 
on the resumption of work on isolated Langendorf 
hearts of rats after simulating total 60‑min 
ischemia (M±m)
Experimental groups % resumed work hearts
Control, n=30 33
Ethoxidol 1×10−4 g/l, n=21 48*




Reliability was calculated by Chi‑square independence criteria. 
*P<0.05 relative to the control group
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is higher by 30 min - by 135%, by 60 min - by 217%, by 
90 min - by 63%, and by 120 min - by 86% [Table 2].
Thus, a comparative analysis of the parameters of the 
effectiveness of ethoxidol, and the combination of ethoxidol 
with rosuvastatin showed the absence of significant 
differences in small doses (1×10−4 g/l). When comparing with 
the parameters of the contractility parameters of the control 
group, it was found that only a large dose (3.8×10−4 g/l) of 
ethoxydol and the combination of ethoxydol with rosuvastatin 
restored the contractility parameters in the reperfusion period, 
reaching maximum values by 60 min, and showing a decrease 
to 120 min. This suggests that the maximum metabolic and 
subsequent stimulating effect on myocardial contractility 
manifests itself for the first 60 min, after which exhaustion 
occurs due to accelerated exhaustion of reserves of energy 
substrates and the degradation of myocardial proteins.
Study of myocardial NADPH activity during 
staining of sections with triphenyltetrazolium 
chloride
In the analysis of myocardial survival, only the hearts that 
resumed work during the reperfusion period while maintaining 
the coronary perfusion rate of at least 3 ml/min were studied.
Total hourly myocardial ischemia and subsequent 2-h 
reperfusion lead to necrosis of 75% of the myocardium [Table 3]. 
The use of ethoxidol (3.8×10−4 g/l) and the combination of 
ethoxidol (3.8×10−4 g/l) with rosuvastatin (4×10−5 g/l) limit the 
zone of necrosis by 14% and 32%, respectively.
CONCLUSION
The study of cardioprotective activity showed that in vitro 
ethoxydol at a dose of 3.8×10−4 g/l can significantly improve 
Table 2: Effect of reperfusion with ethoxydol and combination of ethoxydol with rosuvastatin on the contractility 
parameters of isolated Langendorf hearts of rats after simulating total 60‑min ischemia (M±m; n=10)
Experimental group Parameters
HR IVP +dp/dt -dp/dt
Parameters of contractility at 30 min reperfusion
Control 100±12 8±2 185±24 162±25
Ethoxidol 1×10−4 g/l 102±16 12±2 181±35 160±30
Ethoxidol 3.8×10−4 g/l 129±10 14±2* 488±63* 284±24*
Ethoxidol 3.8×10−4 g/l+rosuvastatin 4×10−5 g/l 98±12 12±1 428±26* 381±54*
Parameters of contractility at 60 min reperfusion
Control 151±10 11±2 268±15 161±20
Ethoxidol 1×10−4 g/l 169±13 11±2 294±23 182±12
Ethoxidol 3.8×10−4 g/l 161±16 23±3* 564±68* 537±29*
Ethoxidol 3.8×10−4 g/l+rosuvastatin 4×10−5 g/l 178±12 27±3* 597±41* 510±31*
Parameters of contractility at 90 min reperfusion
Control 176±18 16±2 293±19 236±28
Ethoxidol 1×10−4 g/l 164±14 16±2 302±31 295±31
Ethoxidol 3.8×10−4 g/l 180±17 28±2* 403±45* 320±44
Ethoxidol 3.8×10−4 g/l+rosuvastatin 4×10−5 g/l 212±21 26±4* 423±42* 385±27*
Parameters of contractility at 120 min reperfusion
Control 154±18 13±1 343±26 250±25
Ethoxidol 1×10−4 g/l 152±22 17±1 359±26 257±21
Ethoxidol 3.8×10−4 g/l 167±14 21±1* 356±28 335±33
Ethoxidol 3.8×10−4 g/l+rosuvastatin 4×10−5 g/l 177±14 25±2* 474±39* 467±23*
HR: Heart rate (beats/min), IVP: Intraventricular pressure (mmHg), + dp/dt, ‑ the maximum rate of contraction (mmHg/s), dp/dt is the 
maximum relaxation rate (mmHg/s), *P<0.05 relative to the control group
Table 3: The effect of a 120‑min reperfusion of 
ethoxydol and a combination of ethoxydol with 
rosuvastatin on the volume of myocardial necrosis 
with total 60‑minute ischemia (% of total myocardial 
volume, M±m, n=10)
Experimental group Size of necrosis, %
Control 75±3
Ethoxidol 1×10−4 g/l 65±4
Ethoxidol 3.8×10−4 g/l+rosuvastatin 
4×10−5 g/l
51±5*
*P<0.05 compared to the control group
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the morphofunctional state of cardiomyocytes, which is 
manifested in an increase in the proportion of postischemic 
cardiac resumption, reduction of ischemic contracture, and 
recovery of contractility during the reperfusion period. 
The use of a combination of rosuvastatin (4×10−5 g/l) with 
ethoxydol (3.8×10−4 g/l) resulted in a significant increase in 
the cardioprotective effect. These data suggest the need for 
further preclinical study of these in vivo pharmacotherapeutic 
regimens in laboratory animals. Extrapolating the results 
obtained to the whole organism of a laboratory rat, it can be 
assumed that the effective concentration of ethoxydol, which 
allows correction of ischemic myocardial damage, will vary 
from 50 to 90 mg/kg.
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